[1] Le MH,Yeo YH,Li X,et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2022,20(12):2809-2817.e28.
[2] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:a systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[3] Liu Y,Zheng J,Hao J,et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med,2022,11(5):1310-1323.
[4] Kanwal F,Kramer JR,Mapakshi S,et al. Risk of Hepatocellular Cancer in Patients with Non-alcoholic Fatty Liver Disease. Gastroenterology,2018,155(6):1828-1837.e2
[5] Younossi Z,Stepanova M,Ong JP,et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol,2019,17(4):748-755.e3.
[6] Alexander MT,Loomis AK,Der Lei JV, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine,2019,17(1):95.
[7] Kramer JR,Natarajan Y,Dai J,et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Hepatology,2022,75(6):1420-1428.
[8] Yang JD,Ahmed F,Mara KC,et al. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology, 2020,71(3):907-916.
[9] Chen J,Song S,Li X,et al. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies. Saudi J Gastroenterol,2022,28(2):92-100.
[10] Asrih M,Jornayvaz F R. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol,2015:55-65.
[11] Fasiha K,Kramer JR,Li L,et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology,2020,71(3):808-819.
[12] Rustgi VK,Li Y,Gupta K,et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology,2021,161(1):171-184.e10.
[13] Lassailly G,Caiazzo R,Ntandja-Wandji LC,et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology,2020,159(4):1290-1301.e5.
[14] Ascha MS,Hanouneh IA,Lopez R,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology,2010,51(6):1972-1978.
[15] Kimura T,Tanaka N,Fujimori N,et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol,2018,24(13):1440-1450.
[16] Ponziani FR,Bhoori S,Castelli C,et al, Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology,2018,69(1):107-120.
[17] Wenrui W,Longxian L,Ding S,et al. Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model. Front Microbiol,2017,8:1804.
[18] Stender S,Loomba R. PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality. Hepatology, 2020,71(3):777-779.
[19] Singal AG,Manjunath H,Yopp AC,et al. The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma:A Meta-analysis. Am J Gastroenterol,2014,109(3):325-334.
[20] Stine JG,Wentworth BJ,Alex Z,et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther,2018,48(7):696-703.
[21] Babak O,Bashkirova A. Parameters of Carbohydrate Metabolism and Expression of Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease and Hypertensive Depending on Lipid Parameters. Georgian Med News,2018,(284):59-65.
[22] Huang DQ,El-Serag HB,Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions,risk factors and prevention. Nat Rev Gastroenterol Hepatol,2020,18(4):223-238.
[23] Ahn SY,Kim SB,Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol, 2020, 2020:4873875.
[24] Chen VL,Yeh ML,Yang JD,et al. Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma. Hepatology Communications, 2020,5(1):122-132.
[25] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[26] Marchesini G,Day CP,Dufour JF,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts,2016,59(6):1121-1140.
[27] Lange NF,Radu P,Dufour JF. Prevention of NAFLD-associated HCC:role of lifestyle and chemoprevention. J Hepatology,2021,75(5):1217-1227.
[28] Galle PR,Forner A,Llovet JM,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology,2018,69(1):182-236.
[29] Marrero JA,Kulik LM,Sirlin CB,et al. Diagnosis,Staging and Management of Hepatocellular Carcinoma:2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2018,68(2):723-750.
[30] Singal AG,Zhang E,Narasimman M,et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis:A meta-analysis. J Hepatol, 2022,77(1):128-139.
[31] Kikuchi L,Oliveira CP,Alvares-Da-Silva MR,et al. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients:Applicability of the BCLC Staging System. Am J Clin Oncol,2016,39(5):428-432.
[32] Llovet JM,Kelley RK,Villanueva A,et al. Hepatocellular carcinoma. Nat Rev Dis Primers,2021,7(1):6.
[33] Koh MX,Hjtm A,Yi B,et al. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. J Am Coll Surg,2019,229(5):467-478.
[34] Su CW,Chau GY,Hung HH,et al. Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Ann Surg Oncol,2015,22(7):2253-2261.
[35] Su JY,Deng ZJ,Teng YX,et al. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease:meta-analysis. BJS Open,2023,7(1):zrac167.
[36] Bc A,Vaab E,Mtb A,et al. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. Ann Hepatol,2019,18(6):855-861.
[37] Mikolasevic I,Filipec-Kanizaj T,Mijic M,et al. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol,2018,24(14):1491-1506.
[38] Conzen KD,Vachharajani N,Collins K,et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. HPB (Oxford),2015,17(3):251-257.
[39] Wong CR,Njei B,Nguyen MH,et al. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2017,46(11-12):1061-1069.
[40] Llovet JM,Baere TD,Kulik L,et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol,2021,18(5):293-313.
[41] Salem R,Johnson GE,Kim E,et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology,2021,74(5):2342-2352.
[42] Young S,Sanghvi T,Rubin N,et al. Transarterial Chemoembolization of Hepatocellular Carcinoma:Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis. Cardiovasc Intervent Radiol,2020,43(1):65-75.
[43] Reig M,Forner A,Rimola J,et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol,2022,76(3):681-693.
[44] Haber PK,Puigvehí M,Castet F,et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology,2021,161(3):879-898.
[45] Finn RS,Qin S,Ikeda M,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med,2020,382(20):1894-1905.
[46] Pfister D,Núez N,Pinyol R,et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature,2021,592(7854):450-456. |
